Show simple item record

dc.contributor.advisorHadler-Olsen, Elin
dc.contributor.authorGussgard, Anne Margrete
dc.date.accessioned2015-10-01T14:44:46Z
dc.date.available2015-10-01T14:44:46Z
dc.date.issued2015-06-17
dc.description.abstractBackground: Radiotherapy causes oral mucositis (OM) that is painful and disrupts eating, talking, social activities and general health. OM may even interrupt cancer therapy. Any intervention that can reduce OM will lead to improvement in treatment and quality of life for patients. It is essential to have a suitable tool to measure potentially effective and new treatments against OM. Objective: To determine if the Patient Reported Oral Mucositis Symptom (PROMS) scale provides a more accurate tool for assessment of oral mucositis than conventional methods based solely on clinician-assessed recordings in patients receiving radiation for head and neck malignancy. Methods: Fifty study participants were examined clinically once before radiotherapy and thereafter twice weekly during the course of their 6-7 weeks treatments and once again post radiotherapy. OM was evaluated clinically according to commonly used clinical assessment tools. The patient-reported OM symptoms were recorded on PROMS-questionnaires. The relationships between PROMS data and clinical data were appraised with Spearman rank correlation tests at the different time points, using robust repeated measures mixed linear models. ANOVA were applied for comparisons of changes of PROMS scale values upon transitions between different sizes of OM ulceration. Simple bivariate tests were used for comparison of characteristics of study participants. Results: Thirty-three participants completed the study. Significant correlations (p<.001) were seen between PROMS scores and other clinical assessments of OM at a group level. The correlation between different signs and symptoms over all time points varied markedly on the individual level. The major change in PROMS scale values occurred upon transition from small to medium size of ulceration, rather than from medium to large. The characteristics of the study participants in different sub-cohorts defined by high and low correlations, high manifestations & minor complaint and low manifestations & major complaints, were comparable, except for age. Conclusion: The relationship between patient-reported impairment of oral functions and mouth pain caused by OM ulceration is not linear, but rather more curvilinear. Therefore, future interventional studies should adopt less severe outcomes than maximum clinical OM scores as primary outcomes. Patient-reported outcomes (PROs) should be incorporated in any interventional studies regarding OM and the changes of PROs values should be measured on the intra-individual rather than on any inter-individual levels. The PROMS questionnaire may be a useful tool to augment clinical assessment of OM, and a feasible substitute assessment in situations where patients cannot endure oral examinations.en_US
dc.description.doctoraltypeph.d.en_US
dc.description.popularabstractStrålebehandling av hode og hals gir bivirkninger i form av smertefulle sår; oral mucositt. Femti pasienter med hode-hals kreft ble strålebehandlet ved Canadas største kreftsykehus. Under behandlingsperioden som varte 6 eller 7 uker ble munn og svelg undersøkt to ganger i uken samtidig som deltakerne besvarte et spørreskjema, hvor de beskrev hvordan smerten og ubehaget fra sårene i munn og svelg påvirket deres munn-, smak og svelgfunksjoner. Alle deltagerne fikk munnsår. Svarene på spørreskjemaene ble sammenliknet med det kliniske utseende på sårene, og man fant totalt sett et godt samsvar på gruppenivå. Den enkelte pasients opplevelse av ubehag er viktig når man skal vurdere bivirkninger fra strålebehandling. Spørreskjemaet vil være et viktig supplement, og sannsynligvis kunne erstatte en klinisk undersøkelse av munn og svelg i situasjoner hvor pasienten ikke klarer å gape opp. Dette er viktige funn når nye behandlingsformer som skal forebygge eller kurere oral mucositt, skal prøves ut.en_US
dc.identifier.urihttps://hdl.handle.net/10037/8171
dc.identifier.urnURN:NBN:no-uit_munin_7750
dc.language.isoengen_US
dc.publisherUiT The Arctic University of Norwayen_US
dc.publisherUiT Norges arktiske universiteten_US
dc.rights.accessRightsopenAccess
dc.rights.holderCopyright 2015 The Author(s)
dc.rights.urihttps://creativecommons.org/licenses/by-nc-sa/3.0en_US
dc.rightsAttribution-NonCommercial-ShareAlike 3.0 Unported (CC BY-NC-SA 3.0)en_US
dc.subjectVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Onkologi: 762en_US
dc.subjectVDP::Medical disciplines: 700::Clinical medical disciplines: 750::Oncology: 762en_US
dc.subjectVDP::Medisinske Fag: 700::Klinisk odontologiske fag: 830::Oral medisin: 835en_US
dc.subjectVDP::Medisinske Fag: 700::Klinisk odontologiske fag: 830::Oral medisin: 835en_US
dc.titleCancer therapy-induced oral mucositis in head and neck cancer patientsen_US
dc.typeDoctoral thesisen_US
dc.typeDoktorgradsavhandlingen_US


File(s) in this item

Thumbnail
Thumbnail
Thumbnail
Thumbnail
Thumbnail
Thumbnail

This item appears in the following collection(s)

Show simple item record

Attribution-NonCommercial-ShareAlike 3.0 Unported (CC BY-NC-SA 3.0)
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-ShareAlike 3.0 Unported (CC BY-NC-SA 3.0)